# FBXW7 Targets the SPT6‐ΔNp63 Axis for Degradation to Inhibit Esophageal Tumorigenesis Induced by 4‐Nitroquinoline N‐Oxide

**Authors:** Jiagui Zhang, Lu Yin, Xiahong You, Xiufang Xiong, Yi Sun

PMC · DOI: 10.1002/mco2.70662 · MedComm · 2026-03-04

## TL;DR

FBXW7 prevents esophageal cancer by breaking down SPT6 and ΔNp63, and high SPT6 levels with low FBXW7 are linked to worse patient outcomes.

## Contribution

FBXW7 is shown to inhibit esophageal tumorigenesis by targeting the SPT6-ΔNp63 axis for degradation.

## Key findings

- FBXW7 inhibits 4NQO-induced esophageal tumorigenesis but not Pik3CaE545K-induced tumorigenesis.
- FBXW7 promotes degradation of SPT6 and ΔNp63, which are pro-proliferative in ESCC cells.
- High SPT6 and low FBXW7 levels in ESCC tissues correlate with poorer patient survival.

## Abstract

FBXW7 (F‐box and WD repeat domain‐containing 7) is a classic tumor suppressor that promotes ubiquitylation and degradation of various oncoproteins. Although its tumor suppressor role in many types of cancers has been established, whether and how FBXW7 regulates in vivo esophageal tumorigenesis was previously unknown. Here, we report, using genetically modified mouse models, that Fbxw7 inhibits esophageal tumorigenesis induced by the carcinogen 4NQO (4‐nitroquinoline N‐oxide), but not by Pik3CaE545K (phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha), a frequently mutated gene in human esophageal squamous cell carcinoma (ESCC). Mechanistically, FBXW7 depletion causes the accumulation of SPT6 (suppressor of Ty6), a transcriptional elongation factor, which is a novel substrate of FBXW7. SPT6 acts as a transcriptional co‐activator of ΔNp63, which is also a substrate of FBXW7 in ESCC cells. Both SPT6 and ΔNp63, accumulated upon FBXW7 knockdown, contribute to the proliferation of ESCC cells. In clinical human ESCC tissues, the protein levels of SPT6 and FBXW7 are inversely correlated, and high SPT6 levels with low FBXW7 levels predict poorer patient survival. Collectively, FBXW7 acts as a tumor suppressor in ESCC by promoting the degradation of both SPT6 and ΔNp63, and the SPT6‐ΔNp63 axis may serve as a therapeutic target for ESCC.

In normal cells, FBXW7 promotes ubiquitylation and degradation of SPT6 and ΔNp63 to keep their pro‐proliferative functions under control. During esophageal tumorigenesis, FBXW7 is inactivated by mutations or deletion, leading to the accumulation of SPT6 and ΔNp63, with ΔNp63 also being up‐regulated by SPT6. Together with 4NQO‐induced initiation, Fbxw7 deletion‐mediated activation of the SPT6‐ΔNp63 axis promotes ESCC development.

## Linked entities

- **Genes:** FBXW7 (F-box and WD repeat domain containing 7) [NCBI Gene 55294], FBXW7 (F-box and WD repeat domain containing 7) [NCBI Gene 55294], SUPT6H (SPT6 homolog, histone chaperone and transcription elongation factor) [NCBI Gene 6830]
- **Proteins:** FBXW7 (F-box and WD repeat domain containing 7), SUPT6H (SPT6 homolog, histone chaperone and transcription elongation factor)
- **Chemicals:** 4-nitroquinoline N-oxide (PubChem CID 5955), 4NQO (PubChem CID 5955)
- **Diseases:** esophageal squamous cell carcinoma (MONDO:0005580), ESCC (MONDO:0005580)

## Full-text entities

- **Genes:** Trp63 (transformation related protein 63) [NCBI Gene 22061] {aka Ket, P51/P63, P63, P73l, Tp63, Trp53rp1}, Pik3ca (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 18706] {aka 6330412C24Rik, caPI3K, p110, p110alpha}, ITCH (itchy E3 ubiquitin protein ligase) [NCBI Gene 83737] {aka ADMFD, AIF4, AIP4, NAPP1}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, TP63 (tumor protein p63) [NCBI Gene 8626] {aka AIS, B(p51A), B(p51B), EEC3, KET, LMS}, SUPT6H (SPT6 homolog, histone chaperone and transcription elongation factor) [NCBI Gene 6830] {aka SPT6, SPT6H, emb-5}, Fbxw7 (F-box and WD-40 domain protein 7) [NCBI Gene 50754] {aka 1110001A17Rik, AGO, Cdc4, Fbw7, Fbwd6, Fbx30}, Plekhf2 (pleckstrin homology domain containing, family F (with FYVE domain) member 2) [NCBI Gene 71801] {aka 1110070J07Rik, ZFYVE18}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, Ei24 (etoposide induced 2.4 mRNA) [NCBI Gene 13663] {aka PIG8}, Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, PDPK1 (3-phosphoinositide dependent protein kinase 1) [NCBI Gene 5170] {aka PDK1, PRO0461}, Uap1l1 (UDP-N-acetylglucosamine pyrophosphorylase 1 like 1) [NCBI Gene 227620] {aka 5730445F03Rik}, Cpd (carboxypeptidase D) [NCBI Gene 12874] {aka D830034L15Rik}, MCL1 (MCL1 apoptosis regulator, BCL2 family member) [NCBI Gene 4170] {aka BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, Mcl-1}, IL27RA (interleukin 27 receptor subunit alpha) [NCBI Gene 9466] {aka CRL1, IL-27RA, IL27R, TCCR, WSX1, zcytor1}, NEDD4 (NEDD4 E3 ubiquitin protein ligase) [NCBI Gene 4734] {aka NEDD4-1, RPF1}, FBXW7 (F-box and WD repeat domain containing 7) [NCBI Gene 55294] {aka AGO, CDC4, DEDHIL, FBW6, FBW7, FBX30}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, FAT1 (FAT atypical cadherin 1) [NCBI Gene 2195] {aka CDHF7, CDHR8, FAT, ME5, hFat1}, Brca1 (breast cancer 1, early onset) [NCBI Gene 12189], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], SND1 (staphylococcal nuclease and tudor domain containing 1) [NCBI Gene 27044] {aka TDRD11, TSN, Tudor-SN, p100}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, RCHY1 (ring finger and CHY zinc finger domain containing 1) [NCBI Gene 25898] {aka ARNIP, CHIMP, PIRH2, PRO1996, RNF199, ZCHY}, CCNB1 (cyclin B1) [NCBI Gene 891] {aka CCNB}, KDM1A (lysine demethylase 1A) [NCBI Gene 23028] {aka AIMAH3, AOF2, BHC110, CPRF, KDM1, LSD1}, Lsm14a (LSM14A mRNA processing body assembly factor) [NCBI Gene 67070] {aka 2700023B17Rik, Tral, mRAP55A}, SKP1 (S-phase kinase associated protein 1) [NCBI Gene 6500] {aka EMC19, OCP-II, OCP2, SKP1A, TCEB1L, p19A}, EGR1 (early growth response 1) [NCBI Gene 1958] {aka AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268}, TDRD1 (tudor domain containing 1) [NCBI Gene 56165] {aka CT41.1}, NEDD8 (NEDD8 ubiquitin like modifier) [NCBI Gene 4738] {aka NEDD-8}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, PLK1 (polo like kinase 1) [NCBI Gene 5347] {aka PLK, STPK13}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, Pdpk1 (3-phosphoinositide dependent protein kinase 1) [NCBI Gene 18607] {aka Pdk1}, Gsk3b (glycogen synthase kinase 3 beta) [NCBI Gene 56637] {aka 7330414F15Rik, 8430431H08Rik, GSK-3, GSK-3beta, GSK3}, MAP4 (microtubule associated protein 4) [NCBI Gene 4134], TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, IL31RA (interleukin 31 receptor A) [NCBI Gene 133396] {aka CRL, CRL3, GLM-R, GLMR, GPL, IL-31RA}, XRCC4 (X-ray repair cross complementing 4) [NCBI Gene 7518] {aka SSMED, hXRCC4}, KMT2D (lysine methyltransferase 2D) [NCBI Gene 8085] {aka AAD10, ALR, BCAHH, CAGL114, KABUK1, KMS}, LSM14A (LSM14A mRNA processing body assembly factor) [NCBI Gene 26065] {aka C19orf13, FAM61A, RAP55, RAP55A}, Supt6 (SPT6, histone chaperone and transcription elongation factor) [NCBI Gene 20926] {aka 5131400N11Rik, SPT6, Supt6h, mKIAA0162}, Rbm7 (RNA binding motif protein 7) [NCBI Gene 67010] {aka 1200007M24Rik, 1500011D06Rik}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, ERVK-15 (endogenous retrovirus group K member 15) [NCBI Gene 100616443] {aka P1.10, c7_C}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, COL11A2 (collagen type XI alpha 2 chain) [NCBI Gene 1302] {aka DFNA13, DFNB53, FBCG2, HKE5, OSMEDA, OSMEDB}
- **Diseases:** weight loss (MESH:D015431), colorectal cancer (MESH:D015179), deaths (MESH:D003643), glioblastoma (MESH:D005909), EC (MESH:D004938), hyperplasia (MESH:D006965), lymph node metastasis (MESH:D008207), ESCC (MESH:D000077277), head and neck (MESH:D006258), in situ carcinoma (MESH:D002278), adenocarcinoma (MESH:D000230), Tumor (MESH:D009369), EAC (MESH:C536611), dysplasia (MESH:D015792), melanoma (MESH:D008545), colon adenocarcinomas (MESH:D003110), SCCs (MESH:D002294), HNSCC (MESH:D000077195), oncogenic (MESH:D000074723), Esophageal Tumorigenesis (MESH:D063646), mammary tumors (MESH:D015674), developmental defects (MESH:D000094602)
- **Chemicals:** AA (MESH:D000596), urea (MESH:D014508), hematoxylin (MESH:D006416), penicillin (MESH:D010406), glycerol (MESH:D005990), H&amp;E (MESH:D006371), Carbamidomethyl (-), propidium iodide (MESH:D011419), ROS (MESH:D017382), DMSO (MESH:D004121), DAPI (MESH:C007293), formalin (MESH:D005557), MLN4924 (MESH:C539933), alcohol (MESH:D000438), guanosine (MESH:D006151), CHX (MESH:D003513), PBS (MESH:D007854), eosin (MESH:D004801), agarose (MESH:D012685), Cys (MESH:D003545), CO2 (MESH:D002245), quinoline (MESH:C037219), streptomycin (MESH:D013307), Coomassie Brilliant Blue (MESH:C004692), Triton X-100 (MESH:D017830), acetonitrile (MESH:C032159), EDTA (MESH:D004492), NP-40 (MESH:C010615), formic acid (MESH:C030544), NaCl (MESH:D012965), paraffin (MESH:D010232), adenosine (MESH:D000241), ethanol (MESH:D000431), SDS (MESH:D012967), DTT (MESH:D004229), TRIzol (MESH:C411644), 4-Nitroquinoline N-Oxide (MESH:D015112), MG132 (MESH:C072553), Peptides (MESH:D010455), water (MESH:D014867), imidazole (MESH:C029899), CCK8 (MESH:D012844), Ed (MESH:D004540)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** G12D, R465C, A-E, S1143A, T with A, R479L, C for 10-14, H1047R, S462F, E1147A, E545K, R465H, Thr-Pro, R505C
- **Cell lines:** HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), EC109 — Homo sapiens (Human), Esophageal squamous cell carcinoma, Cancer cell line (CVCL_6898), BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), KYSE450 — Homo sapiens (Human), Esophageal squamous cell carcinoma, Cancer cell line (CVCL_1353), KYSE30 — Homo sapiens (Human), Esophageal squamous cell carcinoma, Cancer cell line (CVCL_1351), KYSE150 — Homo sapiens (Human), Esophageal squamous cell carcinoma, Cancer cell line (CVCL_1348)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960059/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960059/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960059/full.md

---
Source: https://tomesphere.com/paper/PMC12960059